Premium
Does a previous course of tripotassium dicitrato bismuthate afect the subsequent chances of successful Helicobacter pylori eradication?
Author(s) -
BELL G. D.,
POWELL K.,
BURRIDGE S. M.,
HARRISON G.,
WEIL J.,
GANT P. W.,
JONES P. H.,
TROWELL J. E.
Publication year - 1992
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1992.tb00054.x
Subject(s) - metronidazole , medicine , helicobacter pylori , gastroenterology , peptic ulcer , antibiotics , microbiology and biotechnology , biology
SUMMARY We have performed a retrospective study of 103 patients with either peptic ulcer or non‐ulcer dyspepsia, infected with metronidazole‐sensitive strains of Helicobacter pylori ( H. pylori ), who were treated with a combination of tripotassium dicitrato bismuthate and metronidazole for a period of at least two weeks. Dual therapy with tripotassium dicitrato bismuthate plus metronidazole showed similarly high eradication rates (≥ 80%) of H. pylori from patients irrespective of age, gender or clinical diagnosis. Most importantly, dual therapy achieved a similar eradication rate of H. pylori infection in 41 patients who had previously been treated with tripotassium dicitrato bismuthate alone or in combination with an antibiotic other than metronidazole. It therefore appears that H. pylori does not become resistant to treatment with tripotassium dicitrato bismuthate.